JPS59501712A - Method for treating itch and composition therefor - Google Patents
Method for treating itch and composition thereforInfo
- Publication number
- JPS59501712A JPS59501712A JP57502942A JP50294282A JPS59501712A JP S59501712 A JPS59501712 A JP S59501712A JP 57502942 A JP57502942 A JP 57502942A JP 50294282 A JP50294282 A JP 50294282A JP S59501712 A JPS59501712 A JP S59501712A
- Authority
- JP
- Japan
- Prior art keywords
- naloxone
- pharmaceutically acceptable
- acceptable salt
- naltrexone
- salt
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 208000003251 Pruritus Diseases 0.000 title claims description 22
- 238000000034 method Methods 0.000 title claims description 14
- 239000000203 mixture Substances 0.000 title claims description 8
- RGPDIGOSVORSAK-STHHAXOLSA-N naloxone hydrochloride Chemical compound Cl.O=C([C@@H]1O2)CC[C@@]3(O)[C@H]4CC5=CC=C(O)C2=C5[C@@]13CCN4CC=C RGPDIGOSVORSAK-STHHAXOLSA-N 0.000 claims description 20
- 230000007803 itching Effects 0.000 claims description 17
- 150000003839 salts Chemical class 0.000 claims description 15
- 229960004127 naloxone Drugs 0.000 claims description 13
- 239000006071 cream Substances 0.000 claims description 8
- 238000011282 treatment Methods 0.000 claims description 8
- 229960005250 naloxone hydrochloride Drugs 0.000 claims description 7
- DQCKKXVULJGBQN-XFWGSAIBSA-N naltrexone Chemical compound N1([C@@H]2CC3=CC=C(C=4O[C@@H]5[C@](C3=4)([C@]2(CCC5=O)O)CC1)O)CC1CC1 DQCKKXVULJGBQN-XFWGSAIBSA-N 0.000 claims description 6
- 229960003086 naltrexone Drugs 0.000 claims description 6
- 239000002674 ointment Substances 0.000 claims description 6
- 239000000243 solution Substances 0.000 claims description 5
- 239000006210 lotion Substances 0.000 claims description 4
- 239000002253 acid Substances 0.000 claims 3
- 230000001225 therapeutic effect Effects 0.000 claims 1
- 239000000739 antihistaminic agent Substances 0.000 description 6
- 241000233866 Fungi Species 0.000 description 4
- 229940125715 antihistaminic agent Drugs 0.000 description 4
- 206010003399 Arthropod bite Diseases 0.000 description 3
- 238000011200 topical administration Methods 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- GUGOEEXESWIERI-UHFFFAOYSA-N Terfenadine Chemical compound C1=CC(C(C)(C)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 GUGOEEXESWIERI-UHFFFAOYSA-N 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- 230000001387 anti-histamine Effects 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 235000019441 ethanol Nutrition 0.000 description 2
- 230000003533 narcotic effect Effects 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- VZSRBBMJRBPUNF-UHFFFAOYSA-N 2-(2,3-dihydro-1H-inden-2-ylamino)-N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]pyrimidine-5-carboxamide Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C(=O)NCCC(N1CC2=C(CC1)NN=N2)=O VZSRBBMJRBPUNF-UHFFFAOYSA-N 0.000 description 1
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 206010013647 Drowning Diseases 0.000 description 1
- 208000017604 Hodgkin disease Diseases 0.000 description 1
- 208000010747 Hodgkins lymphoma Diseases 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- 239000004166 Lanolin Substances 0.000 description 1
- 206010033733 Papule Diseases 0.000 description 1
- 239000004264 Petrolatum Substances 0.000 description 1
- 206010039897 Sedation Diseases 0.000 description 1
- 206010041349 Somnolence Diseases 0.000 description 1
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 1
- 208000024780 Urticaria Diseases 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 229940022663 acetate Drugs 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- 229960001340 histamine Drugs 0.000 description 1
- 239000003906 humectant Substances 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 229940039717 lanolin Drugs 0.000 description 1
- 235000019388 lanolin Nutrition 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 239000008297 liquid dosage form Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000003887 narcotic antagonist Substances 0.000 description 1
- 229940049964 oleate Drugs 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 235000019271 petrolatum Nutrition 0.000 description 1
- 229940066842 petrolatum Drugs 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- QQONPFPTGQHPMA-UHFFFAOYSA-N propylene Natural products CC=C QQONPFPTGQHPMA-UHFFFAOYSA-N 0.000 description 1
- 125000004805 propylene group Chemical group [H]C([H])([H])C([H])([*:1])C([H])([H])[*:2] 0.000 description 1
- 230000036280 sedation Effects 0.000 description 1
- 239000008306 shake lotion Substances 0.000 description 1
- 239000000344 soap Substances 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 229940025703 topical product Drugs 0.000 description 1
- 230000002568 urticarial effect Effects 0.000 description 1
- 229940070710 valerate Drugs 0.000 description 1
- NQPDZGIKBAWPEJ-UHFFFAOYSA-N valeric acid Chemical compound CCCCC(O)=O NQPDZGIKBAWPEJ-UHFFFAOYSA-N 0.000 description 1
- 230000002747 voluntary effect Effects 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/485—Morphinan derivatives, e.g. morphine, codeine
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Emergency Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
Abstract
(57)【要約】本公報は電子出願前の出願データであるため要約のデータは記録されません。 (57) [Summary] This bulletin contains application data before electronic filing, so abstract data is not recorded.
Description
【発明の詳細な説明】 痛痒症を治療する方法およびそのための組成物本発明は、痛痒症（ｐｒｕｒｉｔ ｉｓ ） を幅減するための組成物に関する。[Detailed description of the invention] Methods of treating pruritus and compositions therefor The present invention provides methods for treating pruritus and compositions therefor. The present invention relates to a composition for significantly reducing is).
かゆみ（ｉｔｃｈｉｎｇ ）または痛痒は、普通の皮膚科学的症状である。痛痒 症の原因は初雑であり、そして少ししか理解されていない。かゆみの最高に理解 されている機構は、じんま疹の丘疹（ｕｒｔｉｃａｒｉａｌ ｗｈｅａｌｓ ） および強いかゆみに導く度胸におけるヒスタミンの放出である。。そのようなか ゆみは、伝統的に抗ヒスタミン剤により軽減されてきた。抗ヒスタミン療法はし ばしば有効であるけれども、抗ヒスタミン剤により導かれる鎮静および眠む気は 、それらの有効性を制限する。Itching or itching is a common dermatological symptom. Itching The causes of the disease are primitive and poorly understood. Best understanding of itching The proposed mechanism is urticarial papules. and the release of histamine in the gut leading to intense itching. . Is that so? Itching has traditionally been relieved with antihistamines. antihistamine therapy chopsticks Although often effective, the sedation and drowsiness induced by antihistamines , limiting their effectiveness.
しかしながら、多植のかゆみは、抗ヒスタミン剤によっては容易には軽減されな い。たとえば、ホジキン氏病、きのこ状フンゲス（皮屑悪性）および重篤な黄桓 のような状態は、抗ヒスタミン剤により軽減されない強いかゆみを導く。従って 、そのような治療に応答する蚊刺傷のような原因に基くかゆみの抗ヒスタミン治 療に対する代替でありうるばかりでなくまた、中枢神経系に対する全身性効果に 基く方法に関係する本発明者の先行米国特許第４，１８１．７２６号中に開示さ れた如きものを除き、従来治療することが実際上不可能であった痛痒症の難治性 事例における軽減を更に提供する、重篤なかゆみを軽減するための改善された治 療が要望されている。本発明は、中枢神経系に対する全身効果と無関係のそのよ うな組成物および方法を提供的依存性を生じることが知られておらず、また非耽 溺者に対し基本的に薬理学的活性を発揮しない麻薬拮抗剤である。ナロキソンは 、耽病者に対し麻薬離脱において彼等を助けるために通常注射により投与され、 またあるときには手術の間の麻薬の使用に引続く麻薬性抑うつの部分的逆転のた めに術後患者に投与される。However, itching is not easily relieved by antihistamines. stomach. For example, Hodgkin's disease, fungal fungus and severe fungus This condition leads to severe itching that is not relieved by antihistamines. Therefore , antihistamine treatment of itch based on causes such as mosquito bites that respond to such treatment. Not only can it be an alternative to therapy, but it also has systemic effects on the central nervous system. As disclosed in my prior U.S. Pat. No. 4,181.726 related to the underlying method, Intractable pruritus, which was practically impossible to treat with the exception of cases such as Improved treatments to relieve severe itching, providing further relief in cases Treatment is required. The present invention addresses such We provide such compositions and methods that are not known to cause dependence and are non-indulgent. It is a narcotic antagonist that basically shows no pharmacological activity in drowning victims. Naloxone is , usually administered by injection to addicts to help them with drug withdrawal; and sometimes for partial reversal of narcotic depression following narcotic use during surgery. It is administered to patients postoperatively.
ナロキソンの局所投与は種々の状節における重篤なかゆみの理解において有用で あることが、篤くべきことには見出された。Topical administration of naloxone may be helpful in understanding severe itching in various lesions. Something serious has been discovered.
本発明は、そのような治療の必要な患者における重篤なかゆみを＠滅するための 方法を提供し、該方法はそのような治療の必要な患者に対し、ナロキソンまたは その医薬的に受容しつる塩、ある′いはナルトレキフン（Ｎａ１ｔｒｅｘｏｎｅ ） の治療的有効量を局所投与することからなる。The present invention provides a method for eliminating severe itching in patients in need of such treatment. Provided are methods for administering naloxone or Its pharmaceutically acceptable salts, or Naltrexone .)).
ナロキソン塩酸塩は、デュポン・カンパニー（ＤｕＰｏｎｔ Ｃｏｍｐａｎｙ ） の従属会社であるエンド・ラボラトリーズ・インコーホレーテッド（Ｅｎｄ ｏ Ｌａｂｏｒａｔｏｒｉｅｓ 。Naloxone hydrochloride is manufactured by DuPont Company. ) is a subsidiary of End Laboratories, Inc. (End o Laboratories.
工ｎｃ、）、スチュアート・アベニュー（Ｓｔｅｗａｒｔ Ａｖｅｎｕｅ）、ガ ーデン・シティ（Ｇａｒｄｅｎ Ｃ１ｔｙ） 、ニューヨーク（Ｎｅｗｙｏｒｋ ） １１５６０から商業的に入手しうる。ナロキソンの製造は、米国特許第３． ２５４，０８３号中に開示されている。nc,), Stewart Avenue, Ga. - Garden C1ty, New York ) 11560 commercially available. The production of naloxone is described in U.S. Patent No. 3. No. 254,083.
ここに使用される医薬的に受容される塩なる語は、ば塩酸塩、臭化水素酸塩、ヨ ウ化水素醸塩、アセテート、バレレート、オレエート等を示ス。As used herein, the term pharmaceutically acceptable salts includes hydrochloride, hydrobromide, iodine. Indicates hydrogen uride salt, acetate, valerate, oleate, etc.
局所投与用の液体投薬形は、この技術分野におし１て普通に使用される揮発性希 釈剤、たとえばアルコール、グリコール等を含有する受容しうる乳液、溶液およ び懸濁液を包含する。そのような希釈剤の他に、局所適用組成物はまた、湿潤剤 、乳化剤および懸濁化剤を包含しうる。Liquid dosage forms for topical administration are made from volatile diluted materials commonly used in the art. Acceptable emulsions, solutions and solutions containing diluents such as alcohols, glycols etc. and suspensions. In addition to such diluents, topically applied compositions may also contain humectants. , emulsifying agents and suspending agents.
本発明の実施において、医薬的に受容しうる塩たとえは塩酸塩およびその医薬的 に受容しうる化学的誘導体たとえばｎ−メチルシクログロピル銹導体であるナル トレキフンの形におけるナロキソンは、局所投与用の溶成、ローション、クリー ムおよび軟膏中に、それら局所製品は、１日１から８回まで度胸に適用される。In the practice of this invention, pharmaceutically acceptable salts include the hydrochloride salt and its pharmaceutically acceptable salts. Chemical derivatives acceptable to Naloxone in the form of Trekifun is available as a solution, lotion, and cream for topical administration. In creams and ointments, these topical products are applied to the chest from one to eight times a day.
局所適用された者により経験される軽減は、１時的であるけれども急速である。The relief experienced by those applying topically is temporary but rapid.
例１ ナロキソン塩酸壇１重量％を、エチルアルコール７０容量％およびプロピレング リコール６０容量％力）ら構成される溶液中に合体させ、そして１１才の男子に 対し２４時間以内の２つの蚊刺傷に１日５回適用した。この子供は、各適用の１ ０分以内に彼の力Ｓゆみ力）らの軽減を認め、軽減は２〜４時間持続した。Example 1 1% by weight of naloxone hydrochloride, 70% by volume of ethyl alcohol and propylene. 60% by volume) and an 11-year-old boy. It was applied five times a day to two mosquito bites within 24 hours. This child has 1 of each application. He noticed a reduction in his strength within 0 minutes, and the relief lasted for 2 to 4 hours.
例２ ナロキソン塩酸塩０．０ ５％をオイセリン（ Ｒ．Ｔ．Ｍ ）クリームに合体 させ、そしてきのこ状フンゲスに起因する難治性かゆみを有する６０才の男子の 身体に１日４回適用した。オイセリン（ Ｒ，Ｔ．Ｍ ）クリームは、／クイエ ルスドルフ、インコニホレーテツト（ Ｂｅｉｅｒｓｄｏｒｆ。Example 2 Combine naloxone hydrochloride 0.05% into Eucerin (R.T.M.) cream A 60-year-old man with intractable itching caused by fungus fungus. Applied to the body 4 times a day. Eucerin (R, T.M) cream / Kuie Beiersdorf, Inc.
■ｎｃ．）サウス・ノルウオーク（ Ｓｏｕｔｈ Ｎｏｒｗａ’ｌｋ ）、コネ チカット（ ＣＯｎｎｅｔｉＣｕｔ ） ０ ６ ８ ５ ４ により製造され た合成ラノリン含有クリームである。これは、使用した患者に彼のかゆみからの 何らかの顕著な軽減を提供した最初の局所製品であった。■nc. ) South Norwak, Kone Manufactured by CONnetiCut 0.6.8.5.4 It is a cream containing synthetic lanolin. It was used to give patients relief from his itching. It was the first topical product to provide any significant relief.
例ろ 主にペトロラタムから構成され、そしてナロキ゛ノン塩酸塩肌０１重量％を含有 する軟膏を、きのこ状フンゲスを有する６０才の男子の身体に１日４回適用した 。Just like that Mainly composed of petrolatum and contains 0.1% by weight of naquinone hydrochloride The ointment was applied four times a day to the body of a 60-year-old man with fungus fungi. .
例２におけるナロキサンのより高濃度と同しはとではないけれども、かゆみは減 少した。Although not the same as the higher concentration of naloxane in Example 2, the itching is reduced. It was a little.
例４ ナロキソン塩酸塩肌１重量％を亜鉛シェークローションに合体させ、そして６オ の女子の蚊刺隔に、夏に５回の間隔で１ケ月間適用した。この適用は、かゆみか らの顕著な軽減を提供した。Example 4 Naloxone hydrochloride skin 1% by weight was combined with zinc shake lotion and 6 oz. It was applied five times in the summer for one month to the mosquito bite intervals of girls. This application may cause itching or provided significant relief.
例５ ナロキソン塩酸塩５重量％を軟膏に合体させ、そして３８才の男子の左手上の小 湿疹性斑点に１日４回２日間適用した。かゆみは試鹸軟肯の各適用により皮層科 学的に減少した。Example 5 Naloxone hydrochloride 5% by weight was combined into an ointment, and the small area on the left hand of a 38-year-old male was Applied to eczematous spots 4 times a day for 2 days. Itching can be treated by applying soap to the skin. scientifically decreased.
手続補正書（自発） 昭和５９年５８７９日 特許庁長官殿 ２、発明の名称 ３、補正をする者 事件との関係 特許出願人 ４、代理人 ５、補正命令の日付 昭和 年 月 日 ６６補正により増加する発明の数 ８、補正の内容 別紙のとおりProcedural amendment (voluntary) 5879, 1982 Commissioner of the Patent Office 2. Name of the invention 3. Person who makes corrections Relationship to the incident: Patent applicant 4. Agent 5. Date of amendment order Showa year, month, day Number of inventions increased by 66 amendment 8. Contents of amendment as attached
Claims (1)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/US1982/001152 WO1984000889A1 (en) | 1982-08-25 | 1982-08-25 | Method of treating pruritis and composition therefor |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JPS59501712A true JPS59501712A (en) | 1984-10-11 |
Family
ID=22168155
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP57502942A Pending JPS59501712A (en) | 1982-08-25 | 1982-08-25 | Method for treating itch and composition therefor |
Country Status (5)
| Country | Link |
|---|---|
| EP (1) | EP0116538A4 (en) |
| JP (1) | JPS59501712A (en) |
| AU (1) | AU8952282A (en) |
| DK (1) | DK206584A (en) |
| WO (1) | WO1984000889A1 (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2009534334A (en) * | 2006-04-21 | 2009-09-24 | ディーエスエム アイピー アセッツ ビー．ブイ． | Use of opioid receptor antagonists |
| JP4882744B2 (en) * | 2004-03-30 | 2012-02-22 | 東レ株式会社 | Antidiarrheal |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HU201675B (en) * | 1983-08-26 | 1990-12-28 | Ivan Balkanyi | Process for producing oral pharmaceutical compositions with unappetizing effect |
| US4626539A (en) * | 1984-08-10 | 1986-12-02 | E. I. Dupont De Nemours And Company | Trandermal delivery of opioids |
| US5096715A (en) * | 1989-11-20 | 1992-03-17 | Alko Ltd. | Method and means for treating alcoholism by extinguishing the alcohol-drinking response using a transdermally administered opiate antagonist |
| GB9725114D0 (en) * | 1997-11-28 | 1998-01-28 | Pfizer Ltd | Treatment of pruritus |
| US20090093509A1 (en) * | 2007-10-08 | 2009-04-09 | Tahir Nazir | Methods and Compositions for the Treatment of Pruritus |
| US20140179727A1 (en) | 2012-12-14 | 2014-06-26 | Trevi Therapeutics, Inc. | Methods for treating pruritus |
| US8637538B1 (en) | 2012-12-14 | 2014-01-28 | Trevi Therapeutics, Inc. | Methods for treatment of pruritis |
| US8987289B2 (en) | 2012-12-14 | 2015-03-24 | Trevi Therapeutics, Inc. | Methods for treating pruritus |
| IL318587A (en) | 2018-07-23 | 2025-03-01 | Trevi Therapeutics Inc | Treatment of chronic cough, breathlessness and dyspnea |
| CA3166928A1 (en) | 2020-01-10 | 2021-07-15 | Trevi Therapeutics, Inc. | Methods of administering nalbuphine |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3773955A (en) * | 1970-08-03 | 1973-11-20 | Bristol Myers Co | Analgetic compositions |
| US4181726A (en) * | 1978-11-16 | 1980-01-01 | Bernstein Joel E | Method of alleviating pruritis |
-
1982
- 1982-08-25 JP JP57502942A patent/JPS59501712A/en active Pending
- 1982-08-25 WO PCT/US1982/001152 patent/WO1984000889A1/en not_active Ceased
- 1982-08-25 EP EP19820902866 patent/EP0116538A4/en not_active Withdrawn
- 1982-08-25 AU AU89522/82A patent/AU8952282A/en not_active Abandoned
-
1984
- 1984-04-25 DK DK206584A patent/DK206584A/en not_active Application Discontinuation
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4882744B2 (en) * | 2004-03-30 | 2012-02-22 | 東レ株式会社 | Antidiarrheal |
| JP2009534334A (en) * | 2006-04-21 | 2009-09-24 | ディーエスエム アイピー アセッツ ビー．ブイ． | Use of opioid receptor antagonists |
Also Published As
| Publication number | Publication date |
|---|---|
| EP0116538A4 (en) | 1985-04-25 |
| WO1984000889A1 (en) | 1984-03-15 |
| EP0116538A1 (en) | 1984-08-29 |
| AU8952282A (en) | 1984-03-29 |
| DK206584D0 (en) | 1984-04-25 |
| DK206584A (en) | 1984-04-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2728284B2 (en) | Hemorrhoids and other therapeutic compositions | |
| US6433003B1 (en) | Method for treating hyperhidrosis in mammals | |
| US6524623B1 (en) | Therapeutic compositions and methods of use thereof | |
| Hay et al. | Tioconazole nail solution—an open study of its efficacy in onychomycosis | |
| DE69017596T2 (en) | Use of an opiate antagonist for the production of a medicament to be administered transdermally and a device for transdermal administration. | |
| EP2481747A1 (en) | Methods of treating cutaneous flushing using selective alpha-2-adrenergic receptor agonists | |
| JP2002536321A (en) | Pharmaceutical composition | |
| DE3023588C2 (en) | Use clonidine or its hydrochloride with phentermine to quit smoking | |
| JP2000512996A (en) | Preventive and therapeutic measures for skin sensitization and irritation | |
| US4209505A (en) | Pilocarpine mouthwash for dry mouth relief | |
| US4369190A (en) | Analgesic composition and use thereof to ameliorate intractable pain | |
| JPH01501627A (en) | Composition for treating psoriasis | |
| US20120114743A1 (en) | Transdermal ricinoleic acid compositions | |
| Schutz et al. | Local anaesthetic properties of ambroxol hydrochloride lozenges in view of sore throat | |
| Gupta et al. | Intermittent short duration therapy with fluconazole is effective for tinea capitis | |
| US4395420A (en) | Method and composition for treating pruritis | |
| Diehl | Topical antifungal agents: An update. | |
| EP0116538A1 (en) | Method of treating pruritis and composition therefor | |
| US20060205699A1 (en) | Topical treatment for psoriasis | |
| JPH01246221A (en) | Phenol-containing antitussive agent | |
| US5331012A (en) | Topical pharmaceutical preparation for fever blisters and other viral infections and method of use | |
| EP1318801B1 (en) | Topical analgesic compositions containing aliphatic polyamines and methods of using same | |
| JPH05194219A (en) | Fungicidal agent for topical application | |
| Tigerstedt et al. | Comparison of the analgesic dose‐effect relationships of nefopam and oxycodone in postoperative pain | |
| JP2008531640A (en) | Antifungal composition comprising sertaconazole and hydrocortisone and / or antibacterial quinolone compound |